Skip to content

Ketamine: all studies

Page 120 of 448: studies 1,191 to 1,200 of 4,475, newest first. Back to the ketamine overview

Research

Alfentanil versus fentanyl for emergency department rapid sequence induction with ketamine: A-FAKT, a pilot randomized trial.

The American Journal of Emergency Medicine October 1, 2024 Yichen Zhang, Matthew Miller, Alexander Buttfield et al. 2 citations

Fentanyl is often administered during rapid sequence induction of anesthesia (RSI) in the emergency department (ED) to ameliorate the hypertensive response that may occur. Due to its more rapid onset, the use of alfentanil may be more consistent with both the onset time of the sedative and the commencement of laryngoscopy. As such, we compared the effect of alfentanil and fentanyl on...

Ketamine-dependent patients with persistent psychosis have higher neurofilament light chain levels than patients with schizophrenia.

Asian Journal of Psychiatry October 1, 2024 An-Nie Chung, Ming-Chyi Huang, Tung-Hsia Liu et al. 5 citations

Ketamine can induce persisting psychosis in a subset of individuals who use it chronically and heavily. Previously, we found that the psychopathology and cognitive impairments in patients with ketamine dependence (KD) exhibiting persistent psychosis (KPP) bear resemblances with schizophrenia, albeit with less severity in those with no persistent psychosis (KNP). Furthermore, we also showed that...

DOI: 10.1016/j.ajp.2024.104167 (opens in new tab) Full text (opens in new tab) Ketamine dependence Ketamine psychosis Neurofilament light chain Persistent psychosis +4

Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.

Psychiatry Research October 1, 2024 Je-Yeon Yun, Yong‐Ku Kim 11 citations

Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic...

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Psychiatry Research October 1, 2024 Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al. 17 citations

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...

Sex difference alters the behavioral and cognitive performance in a rat model of schizophrenia induced by sub-chronic ketamine.

Journal of Psychiatric Research October 1, 2024 Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah et al. 21 citations

Schizophrenia is a complex neuropsychiatric disorder with positive, negative, and cognitive symptoms. In rats, sub-chronic administration of ketamine is used for the induction of schizophrenia model. Increased locomotor activity is one of the most important features of psychotic-like symptoms in rodents. On the other hand, risperidone is a potent antipsychotic medication that is approved for...

Fast-acting antidepressant-like effects of ketamine in aged male rats.

Pharmacological Reports October 1, 2024 Elena Hernández-Hernández, Sandra Ledesma-Corvi, Jordi Jornet-Plaza et al. 8 citations

The aging process causes anatomical and physiological changes that predispose to the development of late-life depression while reduces the efficacy of classical antidepressants. Novel fast-acting antidepressants such as ketamine might be good candidates to be explored in the context of aging, especially given the lack of previous research on its efficacy for this age period. Thus, the aim of...

DOI: 10.1007/s43440-024-00636-y (opens in new tab) Full text (opens in new tab) Aging Bdnf Fast-acting antidepressant Ketamine therapy +4

Ketamine alleviates PTSD-like effect and improves hippocampal synaptic plasticity via regulation of GSK-3β/GR signaling of rats.

Journal of Psychiatric Research October 1, 2024 Zixun Wang, Xinyu Hu, Zhongyi Wang et al. 9 citations

Each year, 3-4% of the global population experiences post-traumatic stress disorder (PTSD), a chronic mental disorder with significant social and economic repercussions. Although it has been shown that ketamine can effectively alleviate PTSD symptoms in individuals, the specific mechanism of action underlying its anti-PTSD effects remains unclear. In this study, we investigated how a single,...

GluN2B on Adult-Born Granule Cells Modulates (R,S)-Ketamine's Rapid-Acting Effects in Mice.

The International Journal of Neuropsychopharmacology October 1, 2024 Nicholas E Bulthuis, Josephine C McGowan, Liliana R Ladner et al. 2 citations

Standard antidepressant treatments often take weeks to reach efficacy and are ineffective for many patients. (R,S)-ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be a rapid-acting antidepressant and to decrease depressive symptoms within hours of administration. While previous studies have shown the importance of the GluN2B subunit of the NMDA receptor on...

Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway.

The International Journal of Neuropsychopharmacology October 1, 2024 Gargi Mandal, Madeline Kirkpatrick, Silvia Alboni et al. 12 citations

Understanding the precise mechanisms of ketamine is crucial for replicating its rapid antidepressant effects without inducing psychomimetic changes. Here, we explore whether the antidepressant-like effects of ketamine enantiomers are underscored by protection against cytokine-induced reductions in hippocampal neurogenesis and activation of the neurotoxic kynurenine pathway in our...

DOI: 10.1093/ijnp/pyae041 (opens in new tab) Full text (opens in new tab) Cytokines Apoptosis Hippocampal neurogenesis Kynurenine pathway +3

Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy October 1, 2024 Atif Siddiqui 5 citations

Benzodiazepines and electroconvulsive therapy (ECT) are mainstay treatments for catatonia, a potentially life-threatening psychomotor syndrome characterized by a range of symptoms, including immobility, mutism, stupor, posturing, and sometimes even agitation. It can be a manifestation of various underlying psychiatric or medical conditions, such as schizophrenia, mood disorders, or neurological...

DOI: 10.1002/phar.4612 (opens in new tab) Full text (opens in new tab) Catatonia treatment Ketamine therapy Geriatric psychiatry Schizophrenia management +1